(Q37650389)

21 August 2017

1 reference

title

Targeting cancer with phosphodiesterase inhibitors (English)

1 reference

21 August 2017

0 references

6

Friedrich Grimminger

1 reference

21 August 2017

Rajkumar Savai

1

1 reference

21 August 2017

Soni Savai Pullamsetti

2

1 reference

21 August 2017

Gamal-Andre Banat

3

1 reference

21 August 2017

Norbert Weissmann

4

1 reference

21 August 2017

Hossein Ardeschir Ghofrani

5

1 reference

21 August 2017

Ralph Theo Schermuly

7

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

19

1 reference

21 August 2017

1

1 reference

21 August 2017

117-131

1 reference

The molecular biology of cancer

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

What keeps cells in tissues behaving normally in the face of myriad mutations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Proto-oncogenes and oncogenes in epidermal neoplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Modelling the molecular circuitry of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

An anniversary for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Drug development in oncology: classical cytotoxics and molecularly targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Epac proteins: multi-purpose cAMP targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Localized effects of cAMP mediated by distinct routes of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Integration of calcium with the signaling network in cardiac myocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Tumor reversion: protein kinase A isozyme switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Regulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Alterations in the cAMP signal transduction pathway in mouse lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Basal, cAMP- and cGMP-dependent protein kinases in human brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

An anti-tumor role for cGMP-dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase inhibitors in airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Overview of PDEs and their regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Solution Structure of the cGMP Binding GAF Domain from Phosphodiesterase 5: INSIGHTS INTO NUCLEOTIDE SPECIFICITY, DIMERIZATION, AND cGMP-DEPENDENT CONFORMATIONAL CHANGE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Selective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Role of phosphodiesterases in the regulation of endothelial permeability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

PDE4D plays a critical role in the control of airway smooth muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Identification of human PDE7B, a cAMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase III inhibitors: long-term risks and short-term benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Pharmacologic therapy for intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cilostazol as a Unique Antithrombotic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cilostazol: treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Interaction of metoprolol with lorazepam and bromazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

PDE4 inhibitors: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase inhibitors as anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cyclic 3',5'-nucleotide phosphodiesterases: potential targets for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Expression of PDE11A in normal and malignant human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903485642

10.1517/13543780903485642

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference